Statement on Severe Adverse Event with Marstacimab

The National Bleeding Disorders Foundation (NBDF) has joined with World Federation of Hemophilia (WFH) with issuing a joint statement on a severe adverse event with marstacimab rebalancing agent for hemophilia.

Source: National Bleeding Disorders Foundation, NBDF Notes, January 2026